Skip to main content

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 2:00 p.m. GMT / 9:00 a.m. ET / 6:00 a.m. PT in London, United Kingdom.

A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days.

About Vir Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.87
+2.11 (0.93%)
AAPL  271.53
-0.66 (-0.24%)
AMD  213.54
+12.48 (6.21%)
BAC  54.95
+0.69 (1.27%)
GOOG  306.28
+2.53 (0.83%)
META  667.63
+3.18 (0.48%)
MSFT  485.28
+1.30 (0.27%)
NVDA  180.68
+6.54 (3.76%)
ORCL  194.03
+14.00 (7.78%)
TSLA  479.22
-4.15 (-0.86%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.